Preliminary assessment of low-intensity transcranial magnetic stimulation (TMS) during the treatment for brain glioblastomas.

Authors

null

Ivan A. Popov

Rostov Research Institute of Oncology, Rostov-on-Don, Russian Federation

Ivan A. Popov , Oleg I. Kit , Alla I. Shikhlyarova , Elena M. Frantsiyants , Eduard E. Rostorguev , Dmitriy P. Atmachidi , Natalya N. Timoshkina , Marina A. Gusareva , Dmitrii S. Potemkin , Vitaliy V. Stasov , Yulia Yu. Arapova , Tatiana P. Protasova , Galina V. Zhukova , Sergey E. Kavitskiy , Sergey N. Ignatov , Islam U. Cherkiev , Emzari S. Nikitin , Natalya S. Kuznetsova

Organizations

Rostov Research Institute of Oncology, Rostov-on-Don, Russian Federation

Research Funding

No funding received
None

Background: The standard treatment of malignant brain gliomas, including surgical and radiation therapies, does not provide recovery and a long-time favorable prognosis. The development of technologies and international guidelines on the introduction of electric (TTF) and electromagnetic (TMS) fields in combination treatment for glioblastomas aims to improve immediate results, as shown in experiments on human glioblastoma cell culture. The TMS protocol requires further refinement in parameters of frequency, intensity, and exposure with an assessment of the immediate results of combined treatment. Methods: The study included 60 patients diagnosed with MBG receiving osteoplastic craniotomy with radical (within visible unchanged tissues) tumor removal. Starting from the second day after the surgery, patients of group 1 (n = 30) received 10 sessions of magnetotherapy in the double exposure mode. For the first morning exposure, we used an ultra-low-frequency magnetic field (ULFMF) (0.03 to 9.0 Hz) on the hypothalamus projection area to induce a general antistress reaction. After 2.5-3 hours, local (on the surgical site) TMS exposure with the Neuro-MSD system (Russia) was applied in the pulse algorithm, up to 1 GHz and 5 Hz, 15 mT, 3 min. The induction was reduced exponentially (C = 0.8). The control group 2 (n = 30) did not receive ULFMF or TMS. Magnetic resonance imaging (MRI) was used to determine the volume of tumors (Vt, cm3) and perifocal edema (Ve, cm3) calculated according to the Shrek’s formula for an ellipsoid (V = a×b×c×π/6). Results: Before surgery, Vt = 54.7±5.7cm3 in group 1, in group 2 - Vt = 60.9±8.5cm3 (no statistical differences). After surgery and the subsequent course of ULFMF and TMS, residual tumor volumes in group 1 were 2.5 times lower than in controls (p < 0.05). The difference between Ve values before and after treatment was on average 80.7 cm3 in group 1 and 41.8 cm3 in group 2 (p < 0.05). Conclusions: The inclusion of sequential ULFMF and TMS exposures into postoperative therapy for gliomas, taking into account various vectors of the influence on the projection of centers of homeostasis regulation and the surgical field, as well as the development of programmed modes of biotropic exposure parameters, improves antitumor and anti-edematous effects.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Citation

J Clin Oncol 38: 2020 (suppl; abstr 2545)

DOI

10.1200/JCO.2020.38.15_suppl.2545

Abstract #

2545

Poster Bd #

36

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Genitourinary Cancers Symposium

Randomized trial of five or two MRI-guided adaptive radiotherapy treatments for prostate cancer (FORT).

First Author: Ariel E. E. Marciscano

First Author: Mahadev Potharaju